• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.

作者信息

Callréus Torbjörn

机构信息

Research Unit of Clinical Pharmacology, Institute of Public Health, University of Southern Denmark, Odense, Denmark.

出版信息

Drug Saf. 2006;29(7):557-66. doi: 10.2165/00002018-200629070-00002.

DOI:10.2165/00002018-200629070-00002
PMID:16808549
Abstract

In the process of conceiving a pharmacovigilance plan, as proposed in the International Conference on Harmonisation E2E guideline, the challenge will be how to address possible safety issues with a set of appropriate pharmacovigilance methods. For successful planning, the various and sometimes complex dimensions of the adverse drug reaction in question have to be appropriately described. In order to accommodate these better, a 3-dimensional approach, based on dose, time and patient susceptibility, has recently been proposed (the DoTS model). This approach offers a way of presenting the various dimensions of the problem graphically. The aim of this article is to propose how an extended DoTS model, applied to three different scenarios, could give a better understanding of adverse drug reactions and assist in preparing a pharmacovigilance plan.

摘要

相似文献

1
Use of the dose, time, susceptibility (DoTS) classification scheme for adverse drug reactions in pharmacovigilance planning.
Drug Saf. 2006;29(7):557-66. doi: 10.2165/00002018-200629070-00002.
2
Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.批准前阶段的药物警戒:应对国际人用药品注册技术协调会E2E、国际医学科学组织理事会第VI号指南、美国食品药品监督管理局及欧洲药品管理局/人用医药产品委员会风险管理指南的不断演变的制药行业模式。
Drug Saf. 2006;29(8):657-73. doi: 10.2165/00002018-200629080-00003.
3
International Conference on Harmonisation; guidance on E2E Pharmacovigilance Planning; availability. Notice.国际协调会议;E2E药物警戒计划指南;可获取性。通知。
Fed Regist. 2005 Apr 1;70(62):16827-8.
4
Pharmacoepidemiology and its input to pharmacovigilance.药物流行病学及其对药物警戒的贡献。
Therapie. 2016 Apr;71(2):211-6. doi: 10.1016/j.therap.2016.02.016. Epub 2016 Feb 6.
5
Pharmacovigilance-related topics at the level of the International Conference on Harmonisation (ICH).国际人用药品注册技术协调会(ICH)层面与药物警戒相关的主题
Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):377-87. doi: 10.1002/pds.1043.
6
Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.用于评估药物不良反应的药物警戒:价值、组织与方法
Joint Bone Spine. 2006 Dec;73(6):629-32. doi: 10.1016/j.jbspin.2006.09.002. Epub 2006 Oct 12.
7
Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.加强和合理化欧盟的药物警戒:欧洲将走向何方?对新的欧盟药物警戒立法的审查。
Drug Saf. 2011 Mar 1;34(3):187-97. doi: 10.2165/11586620-000000000-00000.
8
[Pharmacoepidemiology: an another kind of drug surveillance].[药物流行病学:另一种药物监测]
Bull Acad Natl Med. 2015 Feb-Mar;199(2-3):275-9.
9
The future of pharmacovigilance: a personal view.药物警戒的未来:个人观点。
Eur J Clin Pharmacol. 2008 Feb;64(2):173-81. doi: 10.1007/s00228-007-0435-9. Epub 2008 Jan 3.
10
EIDOS: a mechanistic classification of adverse drug effects.EIDOS:一种药物不良反应的机制分类。
Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000.

引用本文的文献

1
The development of a scoring and ranking strategy for a patient-tailored adverse drug reaction prediction in polypharmacy.开发一种针对多药治疗中患者特定不良反应预测的评分和排名策略。
Sci Rep. 2020 Jun 12;10(1):9552. doi: 10.1038/s41598-020-66611-8.
2
Risk undermined in the bilateral pharmaceutical regulatory system in Taiwan.台湾双边药品监管体系中的风险。
J Food Drug Anal. 2018 Apr;26(2S):S3-S11. doi: 10.1016/j.jfda.2017.11.012. Epub 2018 Jan 17.
3
EIDOS: a mechanistic classification of adverse drug effects.EIDOS:一种药物不良反应的机制分类。

本文引用的文献

1
Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors?去氨加压素相关的儿童症状性低钠血症性高血容量症。是否存在预测因素?
J Urol. 2005 Jul;174(1):294-8; discussion 298. doi: 10.1097/01.ju.0000161213.54024.7f.
2
Hyponatremia in elderly patients treated with desmopressin for nocturia: a review of a case series.老年夜尿症患者使用去氨加压素治疗后的低钠血症:病例系列综述
Eur J Clin Pharmacol. 2005 Jun;61(4):281-4. doi: 10.1007/s00228-005-0919-4. Epub 2005 May 4.
3
Biomarkers and surrogate endpoints.
Drug Saf. 2010 Jan 1;33(1):15-23. doi: 10.2165/11318910-000000000-00000.
生物标志物与替代终点
Br J Clin Pharmacol. 2005 May;59(5):491-4. doi: 10.1111/j.1365-2125.2005.02435.x.
4
Recognizing drug-induced liver injury: current problems, possible solutions.识别药物性肝损伤:当前问题与可能的解决方案。
Toxicol Pathol. 2005;33(1):155-64. doi: 10.1080/01926230590522356.
5
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo.迈向基于机制的体内药效学药物-药物相互作用分析
Pharmacol Ther. 2005 Apr;106(1):1-18. doi: 10.1016/j.pharmthera.2004.10.014. Epub 2004 Dec 23.
6
Drug-induced hepatotoxicity: 2005.药物性肝毒性:2005年。
J Clin Gastroenterol. 2005 Apr;39(4 Suppl 2):S83-9. doi: 10.1097/01.mcg.0000155548.91524.6e.
7
Clinical experiences with desmopressin for long-term treatment of nocturia.去氨加压素长期治疗夜尿症的临床经验。
J Urol. 2004 Sep;172(3):1021-5. doi: 10.1097/01.ju.0000136203.76320.f6.
8
Looking to the 21st century: have we learned from our mistakes, or are we doomed to compound them?展望21世纪:我们是从错误中吸取了教训,还是注定要重蹈覆辙?
Pharmacoepidemiol Drug Saf. 2004 Apr;13(4):257-65. doi: 10.1002/pds.903.
9
Joining the DoTS: new approach to classifying adverse drug reactions.加入药物不良反应术语集:药物不良反应分类的新方法。
BMJ. 2003 Nov 22;327(7425):1222-5. doi: 10.1136/bmj.327.7425.1222.
10
Osteoporosis in chronic obstructive pulmonary disease.慢性阻塞性肺疾病中的骨质疏松症。
Eur Respir J Suppl. 2003 Nov;46:64s-75s. doi: 10.1183/09031936.03.00004609.